CtDNA methylation market seen reaching $2.74 billion by 2030

The circulating tumor DNA methylation market is projected to grow from $1.68 billion in 2026 to $2.74 billion by 2030, according to The Business Research Company. North America led the market in 2025, while Asia-Pacific is expected to be the fastest-growing region as cancer diagnostics and liquid biopsy adoption expand.

Why it matters: - CtDNA methylation is becoming a key tool for non-invasive cancer detection, tumor monitoring and treatment tracking. - The market’s projected growth signals rising demand for liquid biopsy-based diagnostics as cancer incidence climbs worldwide. - The shift matters for clinical labs, oncology researchers and diagnostics companies building next-generation testing platforms.

What happened: - The Business Research Company released its Circulating Tumor DNA (CtDNA) Methylation Global Market Report 2026 – Market Size, Trends, And Forecast 2026-2035 on July 30, 2026. - The report values the market at $1.48 billion in 2025 and projects $1.68 billion in 2026. - The report forecasts the market will reach $2.74 billion by 2030. - The report puts the market on a 13.4% CAGR in the near term and a 13.1% CAGR through 2030. - North America held the largest market share in 2025. - Asia-Pacific is expected to be the fastest-growing region during the forecast period.

The details: - CtDNA methylation refers to methyl groups attaching to DNA fragments released into the bloodstream by tumor cells. - The method can reveal cancer-linked methylation patterns from blood samples. - The approach supports non-invasive cancer diagnostics, disease monitoring and treatment response assessment. - Liquid biopsy techniques are central to ctDNA methylation testing. - Historical growth has been supported by better methylation detection methods, wider use of liquid biopsies, ongoing clinical research and demand for personalized cancer treatment. - Future growth is expected to be driven by targeted methylation panels, AI-based methylation analysis, expanded early detection programs, rising oncology research and broader adoption in emerging markets. - The report highlights epigenetic biomarker analysis, enhanced liquid biopsy integration, real-time tumor methylation tracking, non-invasive cancer profiling and advanced ctDNA methylation testing kits as key trends. - Cancer incidence is rising worldwide, driven by aging populations and lifestyle risk factors including poor diet, smoking and physical inactivity. - The National Cancer Institute projected in May 2024 that U.S. cancer survivors would increase from 18.1 million in 2022 to 26 million by 2040. - The report also covers South East Asia, Western Europe, Eastern Europe, South America, the Middle East and Africa.

Between the lines: - The report’s growth outlook suggests ctDNA methylation is moving from a research-heavy segment toward broader clinical use. - North America’s lead reflects stronger diagnostics infrastructure and adoption, while Asia-Pacific’s faster growth points to expanding healthcare investment and cancer awareness. - The emphasis on AI, early detection and real-time tracking shows where product development and commercial competition may concentrate next.

What's next: - The report points to continued expansion through 2030 as early detection programs scale and methylation testing becomes more integrated into oncology workflows. - Market attention is likely to shift toward targeted panels, automation and software that improve interpretation of methylation data. - Download the free sample report - View the full market report

The bottom line: - CtDNA methylation is emerging as a fast-growing diagnostics market with strong upside tied to cancer screening, liquid biopsy adoption and personalized oncology.